Dukes Iain D. 4

What Happened
Iain D. Dukes, a director of Iovance Biotherapeutics, was granted 180,632 deferred restricted stock units (DRSUs) on June 16, 2026. The award was recorded at $0.00 per unit (transaction code A), so there is no immediate cash consideration; the units are a derivative grant representing contingent rights to receive common stock in the future.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (appears timely).
• Grant: 180,632 DRSUs at $0.00; reported as a derivative award (code A). Total immediate value reported: $0.
• Amount owned after transaction: not specified in the filing.
• Footnote summary: each DRSU equals a contingent right to one share under the 2018 Equity Incentive Plan. Vesting occurs on the earlier of (i) the first anniversary of the grant or (ii) the day before the next annual meeting, provided continued service. Issuance of shares is deferred until the earlier of (i) three months after the director leaves service (or upon death/disability), (ii) a change in control, or (iii) ten years from the grant date.
• Transaction type: compensation award to a director (not an open-market purchase or sale).

Context
DRSUs are commonly used for director compensation; they do not represent immediately tradable shares and generally require continued service and satisfaction of vesting/deferred-issuance conditions before shares are issued. This grant should be viewed as a compensation event, not a direct market buy or sell.